Steven Dayan, MD, FACS, first author behind a recent study involving high rates of patient satisfaction following treatment with botulinum toxin, discusses the importance of placing patient satisfaction at the forefront of cosmetic dermatology.
Review insights from a premier dermatology event with expert sessions, hands-on insights, and networking to elevate clinical practice.
A presentation from the 2021 virtual American Academy of Pediatrics Conference & Exhibition urges including examination of the scalp and nails during any skin exam.
In the final part of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.
Misleading marketing and incomplete scientific data have led to widespread misinformation about botulinum toxin products.
The JAK inhibitors have demonstrated efficacy, yet some clinicians are still wary of prescribing them. Amy Spizuoco, DO, FAOCD, shares tips to help clinicians improve their comfort in using them.
List prices of 450 medications have increased 5% overall at the beginning of 2023. More price hikes are expected.
Marcella R. Aquino details issues in differential diagnosis for rashes that mimic allergic skin conditions at the ACAAI Annual Meeting.
Prescribing biologics can require a complex approval and claims process. Creating a tiered system based on office workload can help practices understand and allocate staff time. Outsourcing approvals to pharmacies where possible can also streamline the process.
Steve Feldman, MD, PhD, is part of an atopic dermatitis panel and focuses on strategies to hold pediatric patients and their parents accountable to treatment methods.
Scurto presented integrative medicine pearls at the 2024 Diversity in Dermatology meeting.
Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.
Kamran H. Imam, MD, hopes to unlock insights into the atopic disease burden among Native American populations.
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
Lifestyle behaviors, such as body mass index and smoking, were shown to have a stronger association with psoriasis, regardless of genetic risk.
In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.
A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.
A patient returns to your clinic seeking systemic therapy for her AD while postpartum and breastfeeding. Test your knowledge on injectables.
Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.
Doctors cite more support staff, reduced patient panels among solutions.